PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the industry. With this funding, PlasmaGen has now raised over ₹600 crore to date, demonstrating the confidence of investors in its mission and potential.
PlasmaGen Biosciences is a pioneering company that specializes in the development and manufacturing of plasma-derived therapies. These therapies are used to treat a range of life-threatening diseases, including hemophilia, immunodeficiency disorders, and infectious diseases. The company’s state-of-the-art plasma fractionation facility, located near Bengaluru, is one of only five such facilities in India. This facility enables PlasmaGen to produce high-quality plasma-derived products that cater to the growing demand in the domestic and international markets.
The funding round was led by ViNS Bioproducts, a company that has a strong track record of investing in innovative biotechnology companies. PlasmaGen is also backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime, which have supported the company’s growth and expansion plans. The investment by these esteemed investors is a testament to PlasmaGen’s commitment to delivering high-quality products and its potential to make a significant impact in the global biotechnology industry.
The plasma-derived therapies market is expected to witness significant growth in the coming years, driven by the increasing prevalence of rare and infectious diseases. PlasmaGen is well-positioned to capitalize on this trend, with its advanced manufacturing facility and a strong research and development pipeline. The company’s products have the potential to transform the lives of thousands of patients worldwide, and its commitment to innovation and quality has earned it a reputation as a trusted partner in the industry.
The funding raised by PlasmaGen will be utilized to further expand its manufacturing capabilities, enhance its research and development efforts, and strengthen its commercial presence in the global market. The company plans to invest in new technologies and equipment to increase its production capacity, which will enable it to meet the growing demand for its products. Additionally, PlasmaGen will focus on developing new and innovative products that address the unmet medical needs of patients worldwide.
The Indian biotechnology sector has witnessed significant growth in recent years, driven by the government’s initiatives to promote innovation and entrepreneurship. The sector has attracted significant investments from domestic and international investors, and companies like PlasmaGen are at the forefront of this growth. The company’s success is a testament to the potential of Indian biotechnology companies to make a global impact, and its valuation crossing ₹1,500 crore is a significant milestone in the industry.
In conclusion, PlasmaGen Biosciences’ funding round is a significant development in the Indian biotechnology sector. The company’s valuation crossing ₹1,500 crore is a testament to its potential and the confidence of investors in its mission. With its advanced manufacturing facility, strong research and development pipeline, and commitment to innovation and quality, PlasmaGen is well-positioned to make a significant impact in the global biotechnology industry. As the company continues to grow and expand its presence, it is likely to play an increasingly important role in transforming the lives of patients worldwide.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
